Selectivity and specificity of sphingosine 1-phosphate receptor ligands: "Off-targets" or complex pharmacology?

Frontiers in Pharmacology

Volumn MAY, Issue , 2011, Pages

  Pyne, Nigel J ^a   Pyne, Susan ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bml 241,vpc23019; Cay10444; Jte 013; Sphingosine 1 phosphate

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BML 241; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; SB 649146; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 2; SPHINGOSINE 1 PHOSPHATE RECEPTOR 3; SPHINGOSINE 1 PHOSPHATE RECEPTOR 4; SPHINGOSINE 1 PHOSPHATE RECEPTOR 5; TY 52156; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; NONHUMAN; PHARMACOLOGICAL STIMULATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING;

EID: 84866057339     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00026     Document Type: Article

References (34)

1. Billich, A., Bornacin, F., Devay, P., Mechtcheriakova, D., Urtz, N., and Baumruker, T. (2003). Phosphorylation of the immunomofulatory drug,FTY720 by sphingosine kinase. J. Biol. Chem. 278, 47408-47415.
2. Brinkmann, V., Billich, A., Baumrauker, T., Heining, P., Schmouder, R., Francis, G., Aradhyve, S., and Burton, P. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897.
3. Davis, M. D., Clemens, J. J., Macdonald, T. L., and Lynch, K. R. (2005). Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280, 9833-9841.
4. Dawson, G., and Qin, J. (2011). Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricy-clic antidepressants. Biochem. Biophys. Res. Commun. 404, 321-323.
5. Gräler, M. H., and Goetzl, E. J. (2004). The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein coupled receptors. FASEB J. 18, 551-553.
6. Imasawa, T., Kioke, K., Ishi, I., Chun, J., and Yatomi, Y. (2010). Blockade of sphingosine 1-phosphate receptor 2 signalling attenuates streptozotocininduced apoptosis of pancreatic beta-cells. Biochem. Biophys. Res. Commun. 392, 207-211.
7. Jongsma, M., Hendriks-Balk, M. C., Michel, M. C., Peters, S. L., and Alewijnse, A. E. (2006). BML-241 fails to display selective antagonism at the sphingosine-1-phosphate receptor, S1P(3). Br. J. Pharmacol. 149, 277-282.
8. Jongsma, M., van Unen, J., van Loenen, P. B., Michel, M. C., Peters, S. L., and Alewijnse, A. E. (2009). Different response patterns of several ligands at the sphingosine1-phosphate recep-tor subtype 3 (S1P3). Br. J. Pharmacol. 156, 1305-1311.
9. Kenakin, T. (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15, 598-611.
10. Koide, Y., Hasegawa, T., Takahashi, A., Endo, A., Mochizuki, N., Nakagawa, M., and Nishida, A. (2002). Development of novel EDG3 antagonists using a 3D database search and their structureactivity relationships. J. Med. Chem. 45, 4629-4638.
11. Lahiri, S., Park, H., Laviad, E. L., Lu, X., Bittman, R., and Futerman, A. H. (2009). Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain lengthdependent manner. J. Biol. Chem. 284, 16090-16098.
12. Lim, K. G., Tonelli, F., Li, Z., Lu, X., Bittman, R., Pyne, S., and Pyne, N. J. (2011). FTY720 analogues as sphingosine kinase 1 inhibitors: Enzyme inhibition kinetics, allosterism, proteasomal degradation and actin rearrangement in MCF-7 breast cancer cells. J. Biol. Chem. 286, 1863318640.
13. Long, J. S., Fujiwara, Y., Edwards, J., Tannahill, C., Tigyi, G., Pyne, S., and Pyne, N. J. (2010a). Sphingosine 1-phosphate 4 uses HER2 (ErbB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 285, 35957-35966.
14. Long, J. S., Edwards, J., Watson, C., Tovey, S., Mair, K., Schiff, R., Natarajan, V., Pyne, N. J., and Pyne, S. (2010b). Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor positive breast cancer cells. Mol. Cell. Biol. 30, 3827-3841.
15. Mair, K., Robinson, E., Kane, K., Pyne, S., Brett, R., Pyne, N. J., and Kennedy, S. (2010). Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br. J. Pharmacol. 161, 176-192.
16. Murakami, A., Takasugi, H., Ohnuma, S., Koide, Y., Sakurai, A., Takeda, S., Hasegawa, T., Sasamori, J., Konno, T., Hayashi, K., Watanabe, Y., Mori, K., Sato, Y., Takahashi, A., Mochizuki, N., and Takakura, N. (2010). Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol. Pharmacol. 77, 704-713.
17. Nagaoka, Y., Otsuki, K., Fujita, T., and Uesato, S. (2008). Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol. Pharm. Bull. 6, 1177-1181.
18. Ohmori, T., Yatomi, Y., Osada, M., Kazama, F., Takafuta, T., Ikeda, H., and Ozaki, Y. (2003). Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc. Res. 58, 170-177.
19. Osada, M., Yatomi, Y., Ohmori, T., Ikeda, H., and Ozaki, Y. (2002). Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist. Biochem. Biophys. Res. Commun. 299, 483-487.
20. Oskeritzian, C. A, Price, M. M., Hait, N. C., Kapitonov, D., Falanga, Y. T., Morales, J. K., Ryan, J. J., Milstein, S., and Spiegel, S. (2010). Essential roles of sphingosine-1phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema. J. Exp. Med. 207, 465-474.
21. Payne, S. G., Oskeritzian, C. A., Griffiths, R., Subramanian, P., Barbour, S. E., Chalfant, C. E., Milstien, S., and Spiegel, S. (2007). The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1phosphate receptors. Blood 109, 1077-1085.
22. Pyne, N. J., and Pyne, S. (2008). Sphingosine 1 phosphate, lysophosphatidic acid and growth factor signalling and termination. Biochim. Biophys. Acta 1781, 467-476.
23. Pyne, N. J., and Pyne, S. (2010). Sphingosine 1 phosphate and cancer. Nat. Rev. Cancer 10, 489-503.
24. Pyne, S. Long, J. S., Ktistakis, N. T., and Pyne, N. J. (2005). Lipid phosphate phosphatases and lipid phosphate signalling. Biochem. Soc. Trans. 33, 1370-1374.
25. Salomone, S., Potts, E. M., Tyndall, S., Ip, P. C., Chun, J., Brinkmann, V., and Waeber, C. (2008). Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br. J. Pharmacol. 153, 140-147.
26. Salomone, S., Soydan, G., Ip, P. C., Hopson, K. M., and Waeber, C. (2010). Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries. Pharmacol. Res. 62, 465-474.
27. Salomone, S., and Waeber, C. (2011). Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects. Front. Pharmacol. 2:9. doi: 10.3389/fphar.2011.00009
28. Sensken, S. C, Stäubert, C., Keul, P., Levkau, B., Schoneberg, T., and Gräler, M. H. (2008). Selective activation of Gαi-mediated signalling of S1P3 by FTY720 phosphate. Cell. Signal. 20, 1125-1133.
29. Sukocheva, O., Wadham, C., Holmes, A., Albanese, N., Verrier, E., Feng, F., Bernal, A., Derian, C.K., Ullrich, A., Vadas, M. A., and Xia, P. (2006). Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J. Cell. Biol. 173, 301-310.
30. Tonelli, F., Lim, K. G., Loveridge, C., Long, J., Pitson, S. M., Tigyi, G., Bittman, R., Pyne, S., and Pyne, N. J. (2010). FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promotes its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgenindependent prostate cancer cells. Cell. Signal. 22, 1536-1542.
31. Wamhoff, B. R., Lynch, K. R., Macdonald, T. L., and Owens, G. K. (2008). Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype. Arterioscler. Thromb. Vasc. Biol. 28, 1454-1461.
32. Waters, C., Sambi, B., Kong, K.-C., Thompson, D., Pitson, S. M., Pyne, S., and Pyne, N. J. (2003). Sphingosine 1-phosphate and plateletderived growth factor (PDGF) act via PDGFbeta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle. J. Biol. Chem. 278, 6282-6290.
33. Waters, C. M., Long, J. S., Gorshkova, I., Fujiwara, Y., Connell, M. C., Belmonte, K. E., Tigyi, G., Natarajan, V., Pyne, S., and Pyne, N. J. (2006). Cell migration activated by platelet-derived growth factor receptor is blocked by an inverse agonist of the sphingosine 1-phosphate receptor-1. FASEB J. 20, 509-511.
34. Woodcock, J. M., Ma, Y., Coolen, C., Pham, D., Jones, C., Lopez, A. F., and Pitson, S. M. (2010). Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cell. Signal. 22, 1291-1299.